MTCR — Metacrine Income Statement
0.000.00%
HealthcareSpeculativeMicro Cap
- $25.48m
- -$13.48m
Annual income statement for Metacrine, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.45 | 1.45 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 13.8 | 28.2 | 30 | 36.7 | 61.1 |
Operating Profit | -12.3 | -26.7 | -30 | -36.7 | -61.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -12.3 | -25.8 | -28.9 | -37.3 | -62.2 |
Net Income After Taxes | -12.3 | -25.8 | -28.9 | -37.3 | -62.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -12.3 | -25.8 | -28.9 | -37.3 | -62.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -12.3 | -25.8 | -28.9 | -37.3 | -62.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.473 | -0.996 | -1.12 | -1.44 | -1.48 |
Dividends per Share |